Apart from economic considerations, intermittent low-dose bevacizumab therapy might reduce the risk of known dose-dependent anti-VEGF-induced side effects, such as hypertension, proteinuria and bleeding [14]. The gene discussed is VEGFA; the disease is Hypertension.